TransMedics Group Raises Full-Year Guidance

TransMedics Group's robust second quarter was fueled by its Organ Care System and the National OCS Program segments. Key Points Revenue of $114.3 million, a 118% increase year over year. Full-year revenue guidance increased to $425 million to $445 million. Net income of $12.2 million, improving from a net loss of $1 million in the prior year. TransMedics Group (TMDX 2.77%), a pioneer in organ transplantation technology, released second-quarter earnings on Wednesday that reported an impressive 118% year-over ...